Table 5.
Case-series and prospective studies of EUS-RFA for PanNETs (Reprinted/Adapted from [86]).
| Reference | Year | No. of Patients | Mean Size of Tumor (mm) | Complete Response Rate (%) |
Complications (%) |
Recurrences (%) |
|---|---|---|---|---|---|---|
| Rossi et al. [92] | 2014 | 10 | 16 | 100% | 30% (acute pancreatitis) | 0% |
| Armellini et al. [93] | 2015 | 1 | 20 | 100% | 0% | 0% |
| Pai et al. [97] | 2015 | 2 | 27.5 | 100% | 0% | 0% |
| Lakhtakia et al. [98] | 2016 | 3 | 17 | 100% | 0% | 0% |
| Waung et al. [95] | 2016 | 1 | 18 | 100% | 0% | 0% |
| Bas-Cutrina et al. [94] | 2017 | 1 | 10 | 100% | 0% | Not specified |
| Choi et al. [99] | 2018 | 8 | 19 | 75% | 25% (1 case of abdominal pain; 1 case of acute pancreatitis) | Not specified |
| Thosani et al. [100] | 2018 | 3 | Not specified | 100% | Not specified | Not specified |
| de Mussy et al. [96] | 2018 | 1 | 18 | 100% | 0% | 0% |
| Barthet et al. [101] | 2019 | 12 | 13.1 | 85% | 14% (1 acute pancreatitis, 1 pancreatic duct stenosis) | Not specified |
| Oleinikov et al. [102] | 2019 | 18 | 14.3 | 96% | 0% | 0% |
| de Nucci et al. [103] | 2020 | 10 | 14.5 | 100% | 20% (2 cases of abdominal pain) | 0% |
| Younis et al. [104] | 2022 | 1 | 8.9 | 66.7% | Not specified | Not specified |
| Marx et al. [105] | 2022 | 7 | Not specified | 85.7% | 42% (minor adverse events) | Not specified |
| Ferreira et al. [106] | 2022 | 29 | 14.4 | 73.3% | 10% (acute pancreatitis) | Not specified |